NASDAQ · JSPR
Healthcare · Biotechnology
$0.59
Down-$0.03 (-5.52%)
Updated Oct 6, 2026, 8:18 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · JSPR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
JSPR closed at $0.59 after 20 trading sessions, down 16.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $0.57 | $0.5959 | $0.542 | $0.5928 | 376.09K |
| Oct 2, 2026 | $0.60 | $0.615 | $0.5625 | $0.5652 | 237.39K |
| Oct 1, 2026 | $0.59 | $0.64 | $0.5846 | $0.598 | 294.57K |
| Sep 30, 2026 | $0.62 | $0.6546 | $0.5721 | $0.58 | 540.2K |
| Sep 29, 2026 | $0.6415 | $0.6753 | $0.5841 | $0.6254 | 916.3K |
| Sep 28, 2026 | $0.6063 | $0.6563 | $0.6001 | $0.626 | 251.13K |
| Sep 25, 2026 | $0.5925 | $0.6199 | $0.5787 | $0.6091 | 163.1K |
| Sep 24, 2026 | $0.5923 | $0.5923 | $0.5443 | $0.5854 | 634.4K |
| Sep 23, 2026 | $0.6276 | $0.6476 | $0.5667 | $0.5668 | 429.03K |
| Sep 22, 2026 | $0.629 | $0.6513 | $0.6057 | $0.6229 | 310.12K |
| Sep 21, 2026 | $0.636 | $0.6698 | $0.60 | $0.6027 | 209.36K |
| Sep 18, 2026 | $0.6295 | $0.6497 | $0.60 | $0.6178 | 222.81K |
| Sep 17, 2026 | $0.59 | $0.66 | $0.59 | $0.6341 | 303.56K |
| Sep 16, 2026 | $0.5768 | $0.6093 | $0.56 | $0.5809 | 505.32K |
| Sep 15, 2026 | $0.64 | $0.6438 | $0.5679 | $0.5701 | 402.56K |
| Sep 14, 2026 | $0.66 | $0.6682 | $0.60 | $0.6328 | 404.68K |
| Sep 11, 2026 | $0.6933 | $0.711 | $0.66 | $0.6603 | 294.29K |
| Sep 10, 2026 | $0.69 | $0.73 | $0.69 | $0.7007 | 208.01K |
| Sep 9, 2026 | $0.7009 | $0.7144 | $0.68 | $0.701 | 60.35K |
| Sep 8, 2026 | $0.7389 | $0.74 | $0.6952 | $0.7094 | 189.96K |
The latest Smart Investors Daily articles mentioning JSPR.
Company
Market Activity
Research & News
JSPR research
Company profile and research snapshot.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Piper Sandler | Overweight | — |
| May 15, 2026 | TD Cowen | Hold | — |
| May 15, 2026 | RBC Capital | Sector Perform | — |
| Apr 1, 2026 | Evercore ISI Group | Outperform | — |
| Nov 11, 2025 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
Benzinga · Sep 28, 2026
On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper
Yahoo · Sep 15, 2026
Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the appointments of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory
Yahoo · Sep 9, 2026
REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY. H.C. Wainwright 28th Annual Global Investment ConferencePresentation Date/Time: Wednesda
Benzinga · Aug 14, 2026
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.26) by 61.54 percent. This is a 94.25 percent increase over losses of $(1.74) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning JSPR.
